Nymox Corporation   Report issue

For profit Phase 2 Phase 3
Founded: Montreal QE Canada (1989)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2007
NCT00759135
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

fexapotide (6 trials)

Drugs in Phase 2 Trials (1)

finasteride (Proscar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperplasia (Phase 3)

Lower Urinary Tract Symptoms (Phase 3)

Prostatic Hyperplasia (Phase 3)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2